CPBIO3839.HKValuation Analysis
Based on the blended 10-year P/E and P/B percentiles, the stock currently sits in the “Richly Valued” zone.
As of Oct 16, 2026, CPBIO (3839.HK) trades at a P/E of 10.00x, P/B of 0.82x, P/S of 0.58x, and a dividend yield of 0.00%.
Longitudinal percentile comparison: P/E sits at the 86th percentile over the trailing 10Y window (vs. 66th percentile over 3Y); P/B sits at the 93rd percentile over the trailing 10Y window (vs. 77th percentile over 3Y); P/S sits at the 69th percentile over the trailing 10Y window (vs. 88th percentile over 3Y).
Cross-sectional valuation: its P/E ranks at the 32nd percentile within its industry and the 46th percentile across the broader market.
Shareholder return highlight: Total Shareholder Yield is 0.00%; its historical percentile over the trailing long-term window is still accumulating data.
The P/E and P/B long-window percentiles differ by only 7.4 points, pointing to a consistent valuation read across both metrics. Relative to industry peers, its P/E shows a deeper discount than it does against the broader market. Shareholder returns here are driven almost entirely by cash dividends, with minimal contribution from buybacks. CPBIO operates in the Pharmaceutical Chemistry sector. Data refreshes weekly and is for reference only, not investment advice.
Also listed as: HKG: 3839 · SEHK: 3839 · 3839
Want the full picture on whether CPBIO (3839.HK) is under- or over-valued? See the full 3Y / 5Y / 10Y / 20Y P/E, P/B, P/S, Dividend Yield & Total Shareholder Yield percentile matrix and the interactive ECharts trend chart on this page.
Historical Percentiles by Metric
| Metric | Current | Market Percentile | Industry Percentile | 3Y Pctl | 5Y Pctl | 10Y Pctl | 20Y Pctl |
|---|---|---|---|---|---|---|---|
| P/E (TTM) | 10.00 | ||||||
| P/B (MRQ) | 0.82 | ||||||
| P/S (TTM) | 0.58 | ||||||
| Dividend Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |
| Buyback + Div Yield | 0.00% | 0 | 0 | 0 | 0 | 0 | 0 |